Health
Dyadic C1 protein expression platform explored in fight against COVID-19 – Medical Plastics News
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced…
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced from Dyadics industrially proven proprietary and patented hyper-productive C1 gene expression platform.
The RBD was produced at three grams per liter (3 g/l) in only five days.
Dyadics C1 Rapid Recombinant Protein Manufacturing Platform can manufacture monoclonal antibodies (mAbs) more efficiently and faster than currently existing C…
-
Noosa News20 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
Noosa News21 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
General24 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Business6 hours agoFord CEO makes stunning prediction about artificial intelligence